Examples of using Aprepitant in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
The active substance is aprepitant.
Aprepitant is also an inducer of CYP2C9.
The active substance is aprepitant.
Aprepitant to treat nausea and vomiting.
Tabulated list of adverse reactions- aprepitant.
Aprepitant has been studied at higher doses.
What EMEND contains The active substance is aprepitant.
Aprepitant Regimen(N=520) Standard Therapy N=523.
Emend is a medicine containing the active substance aprepitant.
Aprepitant'- used to stop you feeling sick.
Difference(%) calculated as Aprepitant 40 mg minus Ondansetron 4 mg.
Aprepitant cannot be removed by haemodialysis.
The pharmacological effect of fosaprepitant is attributed to aprepitant.
Aprepitant cannot be removed by haemodialysis.
When administered intravenously fosaprepitant is rapidly converted to aprepitant.
Aprepitant is not excreted unchanged in urine.
Occupancy of brain NK1 receptors by aprepitant correlate well with aprepitant plasma concentrations.
Aprepitant is excreted in the milk of lactating rats.
Effect of other medicinal products on the pharmacokinetics of aprepitant resulting from administration of fosaprepitant 150 mg.
Aprepitant is a neurokinin 1(NK1) receptor antagonist.
Adverse reactions were reported in approximately 4% of adults treated with 40 mg aprepitant compared with approximately 6% of patients treated with 4 mg ondansetron intravenously.
Aprepitant- antiemetic used to reduce vomiting.
Alternative or back-up methods of contraception should be used during treatment with fosaprepitant or aprepitant and for 2 months following the last dose of aprepitant see section 4.5.
Aprepitant is highly protein bound, with a mean of 97.
Elimination Aprepitant is not excreted unchanged in urine.
Aprepitant Regimen(N=520) Standard Therapy N=523.
For the single 40 mg aprepitant dose, no special precautions are considered necessary.
Aprepitant is a substrate and a dose-dependent inhibitor of CYP3A4.
Concomitant administration of aprepitant, a moderate CYP3A inhibitor, had no effect on cabazitaxel clearance.
For fosaprepitant and aprepitant no clinical data on exposed pregnancies are available.